Abstract
IntroductionTo analyze the effects of PRESERFLO on corneal endothelial cell density (ECD).MethodsForty-six eyes that underwent PRESERFLO implantation were followed up for 12 months. Specular microscopy was performed preoperatively and at 1, 3, 6, and 12 months postoperatively to measure central ECD and mean monthly reduction (MMR). Anterior segment optical coherence tomography (AS-OCT) was applied to measure the tube–endothelium (TE < 200 μm, 201–500 μm, > 500 μm) distance. The relationship between TE distance and ECD was analyzed with a linear mixed-effects model.ResultsCentral ECD decreased significantly at 1 year (7.4%, p = 0.04), with an MMR of −15 ± 25 cells/mm2. Regarding TE distance groups, there was an 18% ECD reduction in the < 200 μm group vs. 1% in the > 500 μm group (p = 0.08). Endothelial cell loss was related to TE distance (mean 482.9 ± 238 μm), with a higher rate at 1 month in comparison to 12 months for the same tube position in the anterior chamber (−174.8 ± 65.2 cells/mm2 at 1 month vs. 30.2 ± 11.3 cells/mm2 at 12 months, p < 0.01). From month 6, tubes located > 600 μm from the endothelium showed EC loss close to zero.ConclusionsThe PRESERFLO implant is associated with a loss of EC from the immediate postoperative period that continues over time at lower rates. A shorter TE distance appears to cause more severe ECD loss.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.